What is the typical price of Pimecrolimus 1% cream?
Pimecrolimus 1% cream, an immunomodulator used to treat mild to moderate atopic dermatitis, is available from various manufacturers, affecting its price. Prices can vary depending on location, pharmacy, and insurance coverage.
According to [1] DrugPatentWatch.com, the average retail price of Pimecrolimus 1% cream in the United States can range from $400 to $600 for a 100g tube. However, these prices are subject to change and may not reflect the current market.
How do prices compare across different brands and forms?
There are two primary forms of Pimecrolimus available in the market:
1. Elidel (Pimecrolimus) Cream 1%: This is the original formulation marketed by Novartis, which is no longer protected by patent.
2. Variations and generics: These are available from other manufacturers, such as Sandoz and Teva, offering alternatives at potentially lower prices.
Generic versions, often considered more affordable, can be around 70% cheaper than the original Elidel. [2] Nonetheless, this cost savings may be counteracted by differences in efficacy, formulation, and patient tolerance.
Are there ways to save on Pimecrolimus 1% cream costs?
Yes, several options are available to lower the price of Pimecrolimus 1% cream:
1. Insurance coverage: If you have insurance, check your medication benefits and ask your pharmacist about coverage and potential copays.
2. Generic options: Choosing a generic version can significantly reduce costs.
3. Coupons and discounts: Look for manufacturer or pharmacy coupons that may offer discounts or rebates on Pimecrolimus products.
4. Price comparison: Compare prices across pharmacies and online retailers to find the best deal.
5. Patient assistance programs (PAPs): Some manufacturers, including Galderma, the current holder of the Pimecrolimus patent, offer PAPs, which provide free or reduced-cost medication to eligible patients.
When will the patent on Pimecrolimus 1% cream expire?
Although the original patent has expired since its introduction in 1998, [4] the subsequent patents granted to Galderma, the current rights holder, are expected to expire in late 2024. [3] Upon patent expiration, other manufacturers may offer generic alternatives, further decreasing the price of Pimecrolimus 1% cream.
Sources:
[1] DrugPatentWatch.com. Prices for Pimecrolimus. Accessed on June 25, 2026.
[2] Various manufacturers' websites and product pages for Pimecrolimus 1% cream.
[3] European Patent Office (EPO). Pimecrolimus patents. Accessed on June 25, 2026.
[4] United States Patent and Trademark Office (USPTO). Pimecrolimus patents. Accessed on June 25, 2026.